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Successful implantation is associated with a transient reduction of Tim-3 and 3 
PD-1 expression in peripheral lymphocytes on days 3 and 6, but not on day 9, 4 



















Objective: To compare the changing peripheral levels of immune checkpoint 2 
proteins Tim-3/Galectin-9 (Gal-9) and PD-1/PL-1 over a nine-day period after 3 
blastocyst transfer between women who did and did not conceive.   4 
Design: Prospective observational study. 5 
Setting: A university teaching hospital. 6 
Patients(s): 51 infertile women who were undergoing day-5 blastocyst transfer.  7 
Intervention(s): Serial blood samples were obtained on the day of embryo 8 
transfer (ET), and 3, 6 and 9 days afterwards for measurement of (1) 9 
membranous Tim-3 and PD-1 expression on various peripheral lymphocytes 10 
by flow cytometry; and (2) serum concentrations of ligands Gal-9 and PD-L1 11 
by ELISA.  12 
Main Outcome Measure(s): Membranous Tim-3 and PD-1 expression on 13 
lymphocytes and serum Gal-9 and PD-L1 concentrations and comparison of 14 
results between pregnant and non-pregnant women.  15 
Result(s): In women who conceived, the measurements exhibited three 16 
different types of response: (1) a transient and significant reduction of 17 
Tim-3+NK-like T cells, Tim-3+/PD-1+CD8+ T cells and Tim-3+/PD-1+CD4+ T cells 18 
which returned back to baseline level 9 days after ET; (2) a reduction followed 19 
by steady increase to above baseline level on day 9 (Tim-3+CD56dimNK cells); 20 
(3) a steady increase in expression after ET to reach a level significantly higher 21 
than that of the baseline by day 9 (Tim-3+CD56brightNK cells). Women who did 22 
not conceive showed no significant fluctuation in all the parameters measured 23 




Conclusion(s): Successful blastocyst implantation is associated with a 2 
reduction of Tim-3 and PD-1 expression in peripheral lymphocytes on days 3 3 
and 6, which is no longer apparent on day 9.  4 
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Immunological adaptation is a pre-requisite for endometrial preparation which 3 
is necessary for successful implantation (1). The uterus becomes receptive 4 
during the mid-secretory phase (days 19-23) of the menstrual cycle, commonly 5 
known as the window of implantation (WOI). There are considerable changes 6 
in endometrial immune cell numbers during WOI, especially the uterine natural 7 
killer (uNK) cells, which increase from 40% of the total leukocyte population 8 
during the proliferative phase to 60% during WOI and 70% during early 9 
pregnancy (2). The exact role of uNK cells is unknown but they may play a role 10 
in angiogenesis and decidualization of stromal cells to create a unique 11 
immunological microenvironment suitable for the attachment and invasion of 12 
embryo expressing paternal antigens (3, 4).  13 
However, a limitation of immune cell studies at the maternal fetal interface 14 
is that obtaining suitable tissue is invasive and cannot be repeated at regular 15 
intervals to observe the dynamic changes which occur as the implantation 16 
process progresses. In contrast, peripheral immune parameters may be 17 
measured at repeated regular intervals to examine how peripheral immune 18 
responses change during the implantation process. Recently, it has been 19 
demonstrated that both peripheral and decidual NK cell cytotoxicity is inhibited 20 
by T-cell immunoglobulin mucin-3 (Tim-3) which has higher expression in pNK 21 
cells in the first trimester of pregnancy (5, 6). Tim-3 has been shown to be an 22 
immune checkpoint marker of immune suppression, similar to programmed 23 
death-1 (PD-1), the well-known target for immunotherapy in cancer (7). 24 
Previous studies have demonstrated that together with Tim-3, PD-1 modulates 25 
decidual CD4+T and CD8+T cells to produce Th2 type cytokines which may 26 
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lead to maternal-fetal immune tolerance after implantation (8). However, it is 1 
uncertain to what extent PD-1 and Tim-3 are involved in immunological 2 
adaptation at the very early stages of implantation. 3 
The aim of this study was to compare the serial changes, in the 4 
expression of Tim-3 and PD-1 in peripheral NK, T and NK-like T cells, and the 5 
serum levels of their soluble ligands Galectin-9 (Gal-9) and programmed death 6 
-ligand 1 (PD-L1), in the nine days after embryo transfer, between women who 7 
did and did not conceive.  8 
MATERIALS AND METHODS 9 
Subjects 10 
Women undergoing embryo transfer after in-vitro-fertilization (IVF) or 11 
intracytoplasmic sperm injection (ICSI) treatment at the Assisted Reproductive 12 
Technology Unit, Prince of Wales Hospital, Chinese University of Hong Kong 13 
between November 2018 and August 2019 were recruited into the study.  14 
The inclusion criteria were women (1) having one or two day 5 blastocysts 15 
transferred in fresh or frozen cycles; (2) maternal age 20-40 years old. The 16 
exclusion criteria include: (1) hydrosalpinx; (2) structural uterine abnormalities; 17 
(3) antiphospholipid syndrome; (3) abnormal thyroid function; (4) polycystic 18 
ovarian syndrome; (5) hormonal or metabolic disorders; (6) known clinical 19 
autoimmune disease; (7) undergoing immunotherapy; (8) cancer or 20 
post-cancer status; (9) significant medical complications.  21 
Patients recruitment 22 
All subjects included in this study were recruited on the day of ET following 23 
informed, written consent. They had blood samples taken on the day of ET, 24 
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and 3, 6, 9 days afterwards. This study has been approved by our Institutional 1 
Review Board (CREC Ref: 2014.637).  2 
IVF treatment 3 
Ovarian stimulation was initiated by human menopausal gonadotrophins 4 
(HMG) (Pergonal, Serono, Switzerland) or recombinant follicle stimulating 5 
hormone (rFSH) (Gonad-F, Serono, Switzerland). The ovulation trigger used 6 
was 10,000 units HCG (Profasi, Serono, Switzerland) administered 7 
intramuscularly when there were three or more leading follicles reaching 16 8 
mm or more in diameter on transvaginal ultrasound. Transvaginal oocyte 9 
retrieval was performed 36 h after hCG trigger. Luteal support was 10 
commenced in the evening of oocyte retrieval in the form of vaginal 11 
progesterone, either a 90 mg daily dose of Crinone (Merck, Germany) or 12 
Endometrin (Ferring, Saint-Prex, Switzerland) 100 mg TDS. Blastocysts were 13 
transferred on day 5.  14 
   In the cycle of frozen-thawed embryo transfer, natural cycle and hormonal 15 
replacement treatment cycle were monitored with endometrial thickness, 16 
ovarian activity and hormonal levels, as previously described (9). Blastocysts 17 
were thawed and transferred five days following the estimated day of ovulation 18 
or progesterone administration respectively. 19 
Culture system 20 
Cumulus cells were removed from oocytes with hyaluronidase (Vitrolife, 21 
Goteborg, Sweden). After denudation, all mature oocytes were incubated in 60 22 
μ l G-IVF medium for at least an hour in culture, and then fertilized by 23 
conventional IVF or inseminated by ICSI. Fertilized oocytes were cultured in 24 
G-1 medium (Vitrolife, Goteborg, Sweden) supplemented with 10% serum 25 
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substitute supplement, (SSS (Irvine Scientific, Santa Ana, USA)). On the 1 
morning of day 3 development, each embryo was cleaned and rinsed with G1 2 
medium using a 170-μm pipette (Flexipets, Cook Medical, Bloomington, USA). 3 
Each embryo was individually cultured in G-2 medium (Vitrolife, Goteborg, 4 
Sweden) supplemented with 10% SSS until blastocyst stage. All embryos in 5 
this study were cultured using sequential culture media in 30-μl microdrops 6 
under oil, with incubation conditions of 37.0 °C and 6% CO2/5% O2 balanced in 7 
N2 as previously described by our group(10). 8 
Embryo cryopreservation 9 
All blastocysts included in the FET cycles of this study were cryopreserved by 10 
vitrification on day 5, using a commercial vitrification kit (Vit Kit® Freeze, 11 
90133-SO, Irvine Scientific, Santa Ana, CA, USA) and commercial warming kit 12 
(Vit Kit® Thaw, 90137-SO, Irvine Scientific), following the manufacturer's 13 
instructions. 14 
Confirmation of pregnancy 15 
All subjects included in this study had serum β-hCG measurement on the 16 
blood samples obtained 9 days after ET, according to our routine clinical 17 
practice to verify if pregnancy has occurred. Women who had serum β-hCG 18 
(<10 mIU/L) were included into the non-conception group. Women who had 19 
serum β-hCG (>10 mIU/L) were offered ultrasonography 23 days and 30 days 20 
after ET to confirm viability and location of the pregnancy; those who had 21 
ongoing intrauterine pregnancy beyond 12 weeks of gestation were included 22 
into the conception group. For the purpose of this study, women with 23 
biochemical pregnancy loss and miscarriage were excluded because the main 24 
aim of this study was to examine the changes of peripheral Tim-3 and PD-1 25 
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levels in subjects with normal pregnancy as compared to subjects who did not 1 
conceive. Biochemical pregnancy was defined as one in which the serum level 2 
of β-hCG>10 mIU/L on 9th day after embryo transfer, but no ultrasound 3 
evidence of intrauterine pregnancy at 6 weeks of gestation. Miscarriage was 4 
defined as one in which there was ultrasound evidence of intrauterine 5 
pregnancy but the pregnancy did not progress to beyond 12 weeks of 6 
gestation. 7 
Blood sampling 8 
Peripheral blood was collected for serum and lymphocyte isolation. 3 ml whole 9 
blood sample was obtained and placed into a tube with serum separator clot 10 
activator and EDTA coated tube respectively on the day of blastocyst transfer, 11 
and repeated 3, 6 and 9 days after, abbreviated as D0, D3, D6 and D9. Serum 12 
was separated after centrifuged at 3000 rpm. at 4℃ for 30 min. and stored at 13 
-80℃ for later analysis.  14 
Laboratory measurements  15 
1. Peripheral blood mononuclear cell (PBMC) separation  16 
Peripheral blood was diluted 1:1 with 0.9% saline and lymphocytes were 17 
isolated by Lymphopure Density Gradient Medium (Biolegend, USA) with 18 
centrifuged at 800g for 30 min. After centrifugation, PBMCs formed a defined 19 
cell layer at the plasma Lymphopure interface. The layer of PBMCs were 20 
collected and washed in 1% BSA/PBS. The cells were centrifuged, 21 
resuspended and counted for flow cytometry.  22 
2. Labeling of PBMCs and flow cytometric analysis 23 
1X106 PBMCs were resuspended in 100 μl 1% BSA/PBS per tube and 24 
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incubated with anti-human CD56-BV605, CD3-FITC, CD4-APC/Cy7, 1 
CD8-PE/Cy7 and PD-1-PE or Tim-3-PE purchased from BioLegend (San 2 
Diego, CA, USA) for 30 min. in the dark at 4℃. In parallel, each sample was 3 
incubated with matched isotype control antibodies. Then cells were washed 4 
twice with cold 1% BSA/PBS. The expression of Tim-3 and PD-1 on 5 
CD3+CD4+/CD8+T cells, NK-like T (CD3+CD56+) cells, and CD3-CD56dim/bright 6 
NK cells were assayed by FACS (BD LSRFortessa, USA) and analyzed by 7 
FlowJo version 10 software (Tree Star). A minimum of 100 000 events per 8 
sample were collected for phenotypic analysis. As regards flow cytometry 9 
gating strategy, total lymphocytes were first gated on a forward scatter (FSC) 10 
and side scatter (SSC) and then gated on the CD56bright/dimCD3- population as 11 
NK cells, CD56+CD3+ population as NK-like T cells, CD56-CD3+ population as 12 
T cells which was further gated on the CD8+ or CD4+ population as CD8+ T 13 
cells and CD4+ T cells. These cells were further gated on Tim-3 and PD-1 for 14 
the subsets of interest, namely, Tim3+NK cells, Tim-3+NK-like T cells, Tim-3+ 15 
CD8+ T cells, Tim-3+CD4+ T cells, PD-1+ NK-like T cells, PD-1+CD8+ T cells 16 
and PD-1+CD4+ T cells. 17 
3. Quantification of PD-L1, Gal-9 in serum 18 
The levels of soluble ligands PD-L1 and Gal-9 in serum collected at the same 19 
time points were measured by commercial ELISA kits (R and D Systems, 20 
Minneapolis, USA) according to the manufacturer’s protocols.  21 
Statistical analysis 22 
The observed immune parameters were expressed as mean±standard error of 23 
the mean (SEM). Paired sample t tests or Wilcoxon signed-rank tests were 24 
used to compare the change in percentage of lymphocyte subsets and Tim-3, 25 
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PD-1 levels in lymphocyte subsets at different time-points. The comparison of 1 
results between the pregnant and nonpregnant groups was made by using 2 
independent sample t tests for parametric data or Mann-Whitney U test for 3 
nonparametric data. The difference in qualitative data was compared by 4 
chi-square test. P-values < 0.05 were considered statistically significant in all 5 
statistical tests. The statistical analyses were performed using SPSS (Version 6 
22; SPSS Inc., New York, NK, USA).  7 
RESULTS 8 
Demographics  9 
From November 2018 to August 2019, 60 subjects were recruited. Nine 10 
subjects were excluded because of biochemical pregnancy loss, miscarriage 11 
and ectopic pregnancy. In total, 51 subjects were included in the study, with 33 12 
patients in conception group (all singleton) and 18 in non-conception group. 13 
The demographic details of these two groups are compared in table 1. The 14 
mean (±SD) age of women was 34.9 (±3.2) in the conception group and 37.3 15 
(±1.8) years (P<0.05) in the non-conception group. Otherwise, these was no 16 
difference in baseline FSH, body mass index, duration of infertility, type of 17 
infertility, endometrial thickness on the day of hCG trigger and the number of 18 
blastocysts transferred between the two groups.   19 
Phenotype analysis of peripheral lymphocytes  20 
We investigated the relative proportion of NK cells (CD3-CD56+), T cells 21 
(CD3+CD56-) and NK-like T cells (CD3+CD56+), and the proportion of two NK 22 
cell subtypes (CD56dimNK cells and CD56bright NK cells) and two T cell subsets 23 
(CD4+ and CD8+ T cells) in peripheral blood lymphocytes on the day of 24 
blastocyst transfer, and three, six and nine days after blastocyst transfer in 25 
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women who did and did not conceive. The proportions of lymphocyte subsets 1 
did not alter at any of the time points and there was no significant difference in 2 
the results between women who did or did not conceive for all the time points. 3 
(Table 2).   4 
Levels of Tim-3 expression after ET  5 
The changing levels of Tim-3 expression in women who conceived are shown 6 
in Table 2. On the day of ET, Tim-3 was expressed in 34.82 % of pNK cell 7 
(CD56dimNK cells (35.91%) and CD56brightNK cells (25.58%)), 3.37% of T cells 8 
(CD8+T cells (4.14%) and CD4+ T cells (2.91%)) and 3.96% of NK-like T cells. 9 
On day 3 after ET, a significant (p<0.05) drop in Tim-3 expression was 10 
observed in 4 out of 5 lymphocyte subsets (CD56dimNK cells, CD8+T cells, 11 
CD4+T cells and NK-like T cells). By day 6 after ET, there was a noticeable 12 
reversal of the earlier trend, resulting in a minor increase of Tim-3 expression 13 
in these 4 lymphocyte subsets, although at this stage the expression level was 14 
still significantly different to the baseline (ET). By day 9 after ET, the increased 15 
expression of Tim-3 had continued in all cell types, with Tim-3 expression 16 
being significantly higher than the baseline in CD56dimNK cells and 17 
CD56brihgtNK cells.  18 
The changing levels of Tim-3 in women who did not conceive across the 19 
four time points are also summarized in table 2. There was no significant 20 
change in Tim-3 expression among all 5 lymphocyte subsets on all the time 21 
points examined with the exception of CD56dimNK and CD56bright NK cells on 22 
day 9 after ET, which were significantly (42.17±3.24, 28.11±3.20) higher than 23 
the baseline level (34.49±1.97, 22.02±1.67).  24 




On the day of ET, the percentage of Tim-3+pNK cells, Tim-3+T cells and 1 
Tim-3+NK-like T cells were not significantly different between women who did 2 
and did not conceive. On day 3 after ET, Tim-3 expression in four of the 5 3 
lymphocytes subsets (CD56dimNK cells, CD8+T cells, CD4+T cells and NK-like 4 
T cells) was significantly lower in women who conceived compared to women 5 
who did not. There was no difference in CD56brightNK cells. On day 6, a 6 
significant decrease in Tim-3 positive cell numbers was seen in CD56dimNK 7 
cells, CD4+T cells and NK-like T cells, with no difference in CD8+T cells and 8 
CD56brightNK cells. On day 9, there was no significant difference in Tim-3 9 
expression in all lymphocyte subsets (Figure 2A-E).  10 
 11 
Levels of PD-1 expression after ET 12 
The levels of PD-1 expression in women who conceived after ET are shown in 13 
Table 2. On the day of ET, PD-1 was not expressed in either type of pNK cells, 14 
but in 26.83% of T cells and 31.11% of NK-like T cells. There were similar 15 
proportions of cells expressing PD-1 in the 2 T-cell subtypes: 26.53% of CD8+T 16 
cells and 26.88% of CD4+T cells. On day 3 after ET, a significant (p<0.05) drop 17 
in PD-1 expression was observed only in CD4+T cells. By day 6 after ET, PD-1 18 
expression was significantly lower in both CD4+T cells and CD8+T cells. By day 19 
9 after ET, there was a reversal of the decreasing trend, resulting in an 20 
increase of PD-1 expression in both CD4+T cells and CD8+T cells to the 21 
baseline level. The levels of PD-1 expression in NK-like T cells were not 22 
significantly different at any time point.  23 
In the non-pregnant group, there were no significant changes in the 24 
percentage of PD-1+T cells and PD-1+ NK-like T cells at any of the time points 25 
examined.  26 
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Comparison of PD-1 expression between women who did and did not 1 
conceive 2 
The percentages of PD-1+T cells and PD-1+NK-like T cells were not 3 
significantly different between women who did and did not conceive at all time 4 
points after ET (Figure 2F-H).  5 
Concentration of serum Gal-9 and PD-L1 6 
Figure 2I and 2G show the levels of Gal-9 and PD-L1 in serum of pregnant and 7 
non-pregnant women on days 0-9 after ET. There was no difference in levels of 8 
either ligand in women who conceived and those who did not. 9 
 10 
DISCUSSION  11 
Main findings 12 
In the present study, we found that there is a transient and significant reduction 13 
of Tim-3 and PD-1 expression on the cell surface of peripheral lymphocytes 14 
within 9 days after blastocyst transfer. The findings suggest that the Tim-3 and 15 
PD-1 may be useful immunological biomarkers of successful embryo 16 
implantation. In addition, the study results may also help to elucidate 17 
immunological mechanisms that facilitate implantation.  18 
Proportion of peripheral NK and T cells after ET  19 
We found that the relative proportion of subsets of peripheral NK and T cells 20 
were not changed after ET, regardless of whether conception occurred or not. 21 
Earlier studies in the first trimester of pregnancy also showed that the 22 
proportion of peripheral NK subsets prior to conception is similar to those in the 23 
first trimester of pregnancy (11). Our observation further suggested that there 24 
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is no alteration in numbers of pNK cell and T cell after ET. Taken together, it 1 
suggests that the process of implantation does not significantly alter the 2 
proportion of lymphocyte subsets in peripheral blood.  3 
Changing levels of Tim-3 after ET 4 
We observed a significant but transient decrease in Tim-3 expression in 5 
CD56dimNK cells, T cells and NK-like T cells in the nine days after ET. 6 
Measurement beyond day 9 after ET were not carried out in our study, but 7 
earlier reports suggested that the level of expression of Tim-3 in the peripheral 8 
NK cells remained elevated in the first trimester of pregnancy (6). In addition, 9 
Tim-3 was strongly expressed in decidual NK and T cells (5, 8). Tim-3 was 10 
originally identified as a surface marker for interferon-γ (IFN-γ)-producing 11 
CD4+ T helper 1 (Th1) specific cell and CD8+ T cytotoxic (Tc) T cell whose role 12 
is to suppress inflammatory responses and to facilitate the development of 13 
immunological tolerance through Gal-9 engagement (12, 13). Later studies 14 
have shown that Tim-3 is expressed on other innate immune cells, such as NK 15 
cells, monocyte-macrophages, and dendritic cells and may regulate their 16 
differentiation and functions (14). The abundance of Tim-3 at the site of 17 
embryo implantation has led to the hypothesis that the anti-inflammatory 18 
environment mediated by Tim-3 is a pre-requisite for the establishment of a 19 
successful pregnancy. 20 
The unexpected finding in our study is a significant and transient reduction 21 
in Tim-3 expression after ET. The exact biological mechanism for such a 22 
biphasic response is not clear, but supports the hypothesis that the initial 23 
phase of embryo implantation is associated with a pro-inflammatory response 24 
(1, 15). The implantation site is characterized by the presence of inflammatory 25 
cytokines interleukin-6 (IL-6), IL-8, IL-15, granulocyte-macrophage 26 
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colony-stimulating factor (GM-CSF), CXC chemokine ligand 1(CXCL1), 1 
CC-chemokine ligand 4 (CCL4), osteopontin and tumor necrosis factor (TNF) 2 
which are derived from both endometrial stromal cells and infiltrated immune 3 
cells (15). Precisely coordinated interplay between immune cells, cytokines 4 
and hormones is crucial for the tissue remodeling required for successful 5 
embryo implantation (16). The transient reduction of Tim-3 may indicate that in 6 
peripheral blood the pro-inflammatory response occurs after ET followed by 7 
anti-inflammatory response associated with the increase in Tim-3.  8 
Changing levels of PD-1 after ET 9 
PD-1 expression was not seen in NK cell, but was expressed by T cells and 10 
NK-like T cells. The changing pattern of PD-1 expression after ET in T-cell and 11 
NK like T cells was similar to that of Tim-3, but with subtle differences. There 12 
was a reduction in expression among all three lymphocytes subsets 3-days 13 
after ET, but the reduction was significant in only CD4+T cells. On day 6 after 14 
ET there was a significant reduction of PD-1 expressed in both CD4+T cells 15 
and CD8+T cells. By day 9 after ET, the expression level had returned back to 16 
baseline level in all three subsets. PD-1 in decidual T cells plays a critical role 17 
in the maintenance of maternal tolerance by interacting with PD-L1 expressed 18 
on stromal cells (17), trophoblast cells (18), and antigen presenting cells (19). 19 
Moreover, PD-1 is involved in the T-cell homeostasis, namely the 20 
Th1/Th2/Th17/Tregs immune balance at the maternal fetal interface (20, 21). 21 
Given that both Tim-3 and PD-1 are recognized to be anti-inflammatory 22 
mediators (13, 22); the similar changing pattern after ET supports the 23 
hypothesis that a pro-inflammatory response may be a pre-requisite of early 24 
embryo implantation. However, whether this is also reflected at the fetal 25 
endometrial interface is unknown.  26 
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Tim-3 and PD-1 results in women who did not conceive   1 
In contrast to women who conceived, the expression of Tim-3 and PD-1 in 2 
various lymphocyte subsets in women who did not conceive did not show any 3 
significant changes 3, 6 and 9 days after ET, with the exception of increased 4 
Tim-3 expression on CD56dimNK cells 9 days after ET. This observed increase 5 
in CD56dimNK cells may be a consequence of progesterone therapy used for 6 
luteal support, as it has been reported that physiological concentrations of 7 
progesterone induces Tim-3 expression on pNK cells via the IL-4-STAT6 8 
pathway, either directly or indirectly (6).  9 
There was no difference in expression of PD-1 between subjects who did 10 
and did not conceive in all lymphocyte subsets on all the days examined. The 11 
observation suggests the change in the expression of Tim-3 associated with 12 
successful implantation is more pronounced than that of PD1.   13 
Levels of ligands (Gal-9 & PD-L1)      14 
In contrast to the changes in immune inhibitory receptors Tim-3 and PD-1 15 
expression in lymphocyte subsets, there were no observable changes in the 16 
serum concentration of their respective ligands Gal-9 and PD-L1 3, 6 and 9 17 
days after ET, and no difference in the levels between women who did or did 18 
not conceive. The findings suggest that the initial phase of immune modulation 19 
during pregnancy is primarily, if not entirely, mediated via immune inhibitory 20 
receptors but not their ligands. This is in contrast to the finding of an earlier 21 
study which showed that maternal blood level of Gal-9 and PD-L1 were 22 
significantly elevated after confirmation of pregnancy (equivalent to nine days 23 
after ET), which might be caused by their secretion from trophoblasts (23).  24 
The later observation represents the second phase of immunomodulation in 25 
pregnancy. Gal-9 and PD-L1 are expressed by both haemopoietic and 26 
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non-haemopoietic cells (24, 25). The source of these ligands during pregnancy 1 
might be primarily from trophoblasts since high level of both proteins are 2 
expressed in the placenta (23). Based on animal studies, the function of these 3 
two ligands are proposed to mediate maternal immune tolerance though 4 
binding to immune cells expressing Tim-3 or PD-1(8). Prospectively planned 5 
clinical studies are required to confirm their roles in humans.  6 
Strength of current study 7 
A particular strength of this study is that serial measurements were obtained at 8 
several precisely timed points after ET in a population undergoing the same 9 
treatment. Many earlier studies on immune-modulation of pregnancy involved 10 
a single time point (26, 27), not as precisely timed, usually in terms of 11 
gestational weeks rather than days (23, 28). In addition, the observations in 12 
this study were made in the very early stage of embryo implantation, well 13 
before it is known whether or not the implantation is successful, which enabled 14 
us to study the initial, transient phase of immunomodulation of pregnancy. 15 
Thirdly, we have included in our study two cohorts, one cohort with successful 16 
implantation leading to ongoing pregnancy and the other cohort with failure of 17 
implantation leading to non-conception. The latter cohort serves as a 18 
comparison group with which the observations in the conception cohort could 19 
be meaningfully compared. Finally, we have also obtained baseline 20 
measurement prior to the replacement of embryos in both cohorts, with which 21 
any changes following ET could be compared and quantified; moreover, the 22 
observation that the relevant baseline immunological parameters are the same 23 
between those with success or failure of implantation suggest that these 24 
parameters are unlikely to be confounding factors.   25 
Limitations of current study 26 
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Whilst we have found that successful embryo implantation is associated with a, 1 
transient and significant response in the maternal peripheral blood immune 2 
system, it is not possible to conclude in this study if the lack of a normal 3 
maternal immune response is the cause or consequence of the implantation 4 
failure; further well-designed prospective studies are required. A further 5 
limitation of the study is that the measurements in peripheral blood may not 6 
reflect what is happening at the site of implantation. Other limitations of this 7 
study include the relatively small sample size, which did not enable as to 8 
analyze the possible impact of various confounding variables such as patient 9 
population (different underlying causes of infertility), the type of embryo 10 
transfer cycle (fresh or frozen), the methods of endometrium preparation 11 
(natural or artificial) and embryo quality.  12 
Clinical implication 13 
The significant and transient reduction of Tim-3 and PD-1 was detected on day 14 
3 after ET, but the changes reverted back to normal or above baseline level by 15 
the 9th day after ET. It implies that in order to ascertain if there is an underlying 16 
immune cause of implantation failure, serum markers should be measured as 17 
soon as an embryo is replaced; doing the measurement after the pregnancy 18 
test result is known (9 days after ET) is already too late. The monitoring of any 19 
proposed immune therapy to improve embryo implantation should also 20 
commence prior to confirmation of a pregnancy test result.    21 
CONCLUSION 22 
To conclude, we have found that successful embryo implantation is 23 
characterized by a biphasic immunological response in peripheral blood 24 
lymphocytes, with a transient and significant reduction in Tim-3 and PD-1 25 
expression, signifying a pro-inflammatory response 3-6 days after ET, followed 26 
21 
 
by a rebound increase in Tim-3 expression consistent with the beginning of a 1 
second phase of anti-inflammatory response.   2 
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Figure Legends 5 
Figure 1. Differential Tim-3 and PD-1 expression in pNK, T and NK-like T cells. 6 
(A-C) Gating strategy of peripheral NK cells (CD3-CD56+), T cells (CD3+CD56-), 7 
NK-like T cells (CD3+CD56+), CD8+T cells (CD3+CD56-CD8+ CD4-) and CD4+T 8 
cells (CD3+CD56-CD4+CD8-). (D-G) Gating strategy and representative plots 9 
of flow cytometric analysis of Tim-3+NK cells, Tim-3+NK-like T cells, 10 
Tim-3+CD4+T cells and Tim-3+CD8+T cells. (H-K) Gating strategy and 11 
representative plots of flow cytometric analysis of PD-1+NK cells, PD-1+NK-like 12 
T cells, PD-1+CD4+T cells and PD-1+CD8+T cells. 13 
Figure 2. Comparison of Tim-3 and PD-1 expression on peripheral NK subsets, 14 
NK-like T and T cell subtypes between women who did and did not conceive 15 
over a nine-day period after ET. (A) Tim-3+CD56dimNK, (B) Tim-3+CD56brightNK 16 
cells, (C) Tim-3+CD8+T cells, (D) Tim-3+CD4+T cells, (E) Tim-3+NK-like T cells, 17 
(F) PD-1+CD8+T cells, (G) PD-1+CD4+T cells, (H) PD-1+NK-like T cells. 18 
Significant difference was found in (A), (D) and (E) at three and six days after 19 
ET between two groups. The percentage of (C) was significantly lower in 20 
pregnant women compared with non-pregnant women at three days after ET. 21 
No significant difference was found in (B, F-H). Asterixis indicate comparison 22 
which showed a significantly different result, whereas if the asterixis is not 23 
shown, it means the results were not significantly different. The concentrations 24 
26 
 
of circulating Gal-9 (I) and PD-L1 (J) were compared between pregnant and 1 
non-pregnant women at serial time points. No significant difference in 2 
concentration of serum Gal-9 and PD-L1 was observed within groups and 3 
between two groups. 4 
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